{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:41:06Z","timestamp":1758638466598},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current treatments for non\u2010Hodgkin lymphomas are not optimally effective. Among new agents, bortezomib seems to play a pivotal role in the regulation of several cell pathways involved in the development of lymphomas. After results were obtained with clinical trials, we aimed to observe treatment with bortezomib in everyday clinical practice. We performed a multicenter retrospective analysis to assess the efficacy of bortezomib in heavily pretreated (median number of previous therapies 4, range 2\u20136) lymphoma patients in an off\u2010label setting. Bortezomib therapy was scheduled for 4\u20136 cycles (1.3\u2009mg\/m<jats:sup>2<\/jats:sup> biweekly). Data from 50 patients were collected: 22% had a complete remission, 26% obtained a partial response and the remaining 52% was non\u2010responder. According to histotype, we observed an overall response rate (ORR) of 51.6% in mantle cell lymphomas, an ORR of 60% among follicular lymphoma patients, and an ORR of 50% in the indolent nonfollicular lymphomas. None of diffuse large B\u2010cell lymphoma patients obtained a response. Extra\u2010hematological toxicity was really mild, and peripheral neuropathy occurred in only 5 patients; hematological toxicity was grades 3\u20134 thrombocytopenia in nine patients and grades 3\u20134 neutropenia in only three patients. In conclusion, treatment with bortezomib as single agent resulted safe and effective in a subset of heavily pretreated lymphoma patients with usually poor outcome. New future hypotheses of investigation are indicated. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2036","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T17:54:35Z","timestamp":1351533275000},"page":"179-182","source":"Crossref","is-referenced-by-count":13,"title":["Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study"],"prefix":"10.1002","volume":"31","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Merla","sequence":"additional","affiliation":[{"name":"Unit of Hematology, IRCCS Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Ballerini","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda ospedaliero\u2010universitaria San Martino  Genova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda ospedaliero\u2010universitaria senese  Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[{"name":"Unit of Oncology and Hematology IRCCS Ospedale oncologico di Bari  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"Unit of Hematology  Tricase Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlando","family":"Quintini","sequence":"additional","affiliation":[{"name":"Unit of Hematology Policlinico di Palermo  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda ospedaliero\u2010universitaria Careggi  Firenze Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luigia","family":"Vigliotti","sequence":"additional","affiliation":[{"name":"Unit of Oncology and Hematology Azienda ospedaliera San Sebastiano di Caserta  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Quirini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u2018L. and A. Ser\u00e0gnoli\u2019, S. Orsola\u2010Malpighi Hospital University of Bologna  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-S2-17"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013359"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404959"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07466.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2647"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.857.857","article-title":"A Phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab\u2010naive or \u2010sensitive, follicular lymphoma","volume":"116","author":"Coiffier B","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_22_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25792"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3758.3758","article-title":"The combination of bortezomib and rituximab is effective and safe in relapsed\/refractory indolent nonfollicular and mantle\u2010cell non\u2010Hodgkin lymphoma: a phase II multicenter study by Intergruppo Italiano Linfomi [abstract]","volume":"114","author":"Chiappella A","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70248-5"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2036","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:03:03Z","timestamp":1700629383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/hon.2036"],"URL":"https:\/\/doi.org\/10.1002\/hon.2036","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,29]]}}}